Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a night of sleep pills ease breathing in sleep apnea?

NCT ID NCT06928766

Disease control Sponsor: Flinders University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests whether a combination of two sleep medications, eszopiclone and lemborexant, can help people who have both obstructive sleep apnea and insomnia. The idea is that these drugs may raise the brain's threshold for waking up, allowing more stable breathing during sleep. Researchers will compare one night on the drugs versus one night on a placebo, measuring sleep quality, breathing, and next-day performance in 15 participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of eszopiclone (Lunesta) and lemborexant (Dayvigo), taken together at bedtime for one night
What this could lead to
If it works, this could point toward a new way to treat people who have both obstructive sleep apnea and insomnia, by helping them sleep more soundly without worsening their breathing.
What could go wrong
This is a small, early-phase trial with only 15 participants and a single night of treatment. The drugs may not improve sleep apnea severity, and they carry risks like daytime drowsiness or interactions with other medications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Moderate or more difficulty "staying or initiating asleep" score on the Insomnia Severity Index questionnaire * Obstructive Sleep Apnoea (OSA), Apnoea Hypopnea Index ≥ 10 events/hour * Low arousal respiratory threshold OSA endotype * BMI ≤35 kg/m2 Exclusion Criteria: * Concomitant medications that interact or are contraindicated with eszopiclone, zopiclone, and Lemborexant * Concomitant medications known to influence breathing, sleep, arousal, or muscle physiology * Current pregnancy or breast-feeding * Current or recent other medical conditions likely to affect results or safety

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Insomnia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

insomnia obstructive sleep apnea syndrome sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSA - obstructive sleep apnea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Flinders University, Adelaide Institute for Sleep Health

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.